The reaffirmation of the Outperform rating and maintenance of the $5 price target by Oppenheimer analyst Steven Lichtman indicates a positive outlook for BrainsWay's stock. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.